Core Insights - TScan Therapeutics, Inc. presented positive updated data from the ALLOHA™ Phase 1 heme trial at the 67th American Society of Hematology (ASH) Annual Meeting, highlighting the efficacy and safety of its lead TCR-T therapy candidate, TSC-101 [5][2] - The company announced the completion of enrollment in Cohort C of the Phase 1 ALLOHA trial, with patients treated using a commercial-ready manufacturing process [5][10] - TScan received FDA clearance for investigational new drug (IND) applications for TSC-102-A01 and TSC-102-A03, expanding its heme program to target more patients with limited treatment options [2][5] Financial Performance - Revenue for Q4 2025 was $2.6 million, up from $0.7 million in Q4 2024, and total revenue for the full year 2025 was $10.3 million, compared to $2.8 million in 2024 [6] - Research and development (R&D) expenses for Q4 2025 were $20.0 million, down from $29.4 million in Q4 2024, while full-year R&D expenses increased to $114.2 million from $107.4 million in 2024 [7] - General and administrative (G&A) expenses for Q4 2025 were $6.4 million, compared to $8.0 million in Q4 2024, with full-year G&A expenses rising to $32.0 million from $30.3 million in 2024 [8] Operational Updates - TScan's lead TCR-T therapy candidate, TSC-101, is designed to treat residual disease and prevent relapse in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT) [4] - The company plans to share early clinical data from Cohort C in the second quarter of 2026 and initiate its first Phase 3 trial [2][11] - TScan aims to initiate a Phase 1 study for TSC-102-A01 and TSC-102-A03 in the second half of 2026 [11] Cash Position - As of December 31, 2025, TScan had cash and cash equivalents of $152.4 million, which is expected to fund operations into the second half of 2027 [10][16]

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment [3] Group 1: Company Overview - TScan's lead TCR-T therapy candidate is aimed at treating patients with hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation, specifically in the ALLOHA Phase 1 heme trial [3] - The company has developed multiple TCR-T therapy candidates targeting solid tumors and is working on in vivo engineering methods for these candidates [3] - TScan is also utilizing its target discovery platform to identify novel targets in various T cell-mediated autoimmune disorders [3] Group 2: Upcoming Events - TScan will participate in a hybrid presentation and analyst-led Q&A session at the TD Cowen 46 Annual Health Care Conference on March 4, 2026, at 11:50 a.m. Eastern Time [1] - A webcast of the presentation will be available on the company's website, with an archived replay accessible for 90 days post-event [2]

Core Insights - TScan Therapeutics has reached an agreement with the FDA on the pivotal trial design for TSC-101, which is expected to begin in Q2 2026 [3][4] - The company has decided to prioritize the clinical development of its heme program while pausing enrollment in the solid tumor Phase 1 trial [5][13] - Financial results for Q3 2025 show a revenue increase to $2.5 million, up from $1.0 million in Q3 2024, primarily due to research activities with Amgen [7] FDA Agreement and Clinical Development - The FDA has approved a pivotal trial design for TSC-101 that mirrors the ALLOHA Phase 1 trial, utilizing a biologically-assigned internal control arm [3] - The pivotal trial is anticipated to facilitate efficient enrollment and streamlined assessment of study endpoints [3] - The company has implemented a commercial-ready manufacturing process that reduces manufacturing time by five days, lowering costs and the extent of ex vivo T cell expansion [3] Financial Performance - Revenue for Q3 2025 was $2.5 million, a 150% increase from $1.0 million in Q3 2024 [7] - R&D expenses rose to $31.7 million in Q3 2025 from $26.3 million in Q3 2024, driven by increased manufacturing and clinical activities [8] - General and administrative expenses increased slightly to $7.9 million in Q3 2025 from $7.4 million in Q3 2024 [9] - The net loss for Q3 2025 was $35.7 million, compared to $29.9 million in Q3 2024 [10] Cash Position and Future Plans - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities of $184.5 million, expected to fund operations into the second half of 2027 [10] - Plans to submit IND applications for two additional TCR-T product candidates are set for Q4 2025 [13] - The company aims to share updated clinical data from the ALLOHA Phase 1 heme trial at the upcoming ASH Annual Meeting [4]

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell therapies for cancer treatment [3] - The company will participate in a fireside chat at the Guggenheim 2 Annual Healthcare Innovation Conference on November 12, 2025 [1] - A webcast of the event will be available on the company's website, with an archived replay accessible for 90 days post-event [2] Company Overview - TScan Therapeutics is developing TCR-T therapies aimed at treating patients with hematologic malignancies and preventing relapse after allogeneic hematopoietic cell transplantation [3] - The company has multiple TCR-T therapy candidates for solid tumors and is working on in vivo engineering methods [3] - TScan is utilizing its TargetScan platform to identify novel targets in T cell-mediated autoimmune diseases [3]

Core Insights - TScan Therapeutics, Inc. is focused on developing T cell receptor-engineered T cell therapies for cancer treatment, with significant updates on their clinical trials and financial performance [11] Financial Performance - Revenue for Q2 2025 was $3.1 million, a substantial increase from $0.5 million in Q2 2024, primarily due to research activities related to a collaboration with Amgen [5] - Research and development expenses for Q2 2025 were $32.6 million, up from $26.9 million in Q2 2024, driven by increased laboratory supplies and personnel costs [6] - General and administrative expenses for Q2 2025 were $9.1 million, compared to $7.8 million in Q2 2024, mainly due to higher personnel expenses [7] - The net loss for Q2 2025 was $37.0 million, compared to $31.7 million in Q2 2024, with net interest income of $1.7 million in 2025 and $2.5 million in 2024 [9] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $218.0 million, expected to fund operations into Q1 2027 [9] Clinical Development Updates - The company plans to dose its first solid tumor patients with multiplex TCR-T in Q3 2025 and share safety and preliminary response data in Q1 2026 [2][8] - TScan's lead TCR-T therapy candidate, TSC-101, is designed to treat residual disease in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation [3] - The ImmunoBank is being developed to provide multiple TCR-T therapy candidates targeting various cancer-associated antigens to address tumor heterogeneity [4] Upcoming Milestones - TScan plans to present two-year relapse data from the ALLOHA Phase 1 trial by the end of 2025 [8] - The company expects to initiate a registrational trial for TSC-101 in the second half of 2025, pending regulatory feedback [8] - An investigational new drug (IND) application for TSC-102-A0301 is anticipated to be filed in the second half of 2025 [8]

Core Viewpoint - TScan Therapeutics, Inc. is set to present at the Jefferies Global Healthcare Conference on June 4, 2025, highlighting its focus on T cell receptor-engineered therapies for cancer treatment [1]. Company Overview - TScan Therapeutics is a clinical-stage biotechnology company dedicated to developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed for patients with hematologic malignancies, specifically to prevent relapse after allogeneic hematopoietic cell transplantation, as part of the ALLOHA Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that target diverse antigens and are compatible with multiple HLA types, to create customized multiplex TCR-T therapies for various cancers, including the PLEXI-T Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3].

Core Insights - TScan Therapeutics, Inc. announced the acceptance of an abstract for a poster presentation at the ASGCT 28th Annual Meeting, highlighting its focus on TCR-engineered T cell therapies for cancer treatment [1][2]. Company Overview - TScan is a clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed to prevent relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets across multiple HLA types, to offer customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Presentation Details - The poster presentation titled "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation" will take place on May 13 from 6:00 - 7:30 p.m. Central Time [2]. - The presentation will be held in the Poster Hall, Hall I2, and materials will be available on the company's website post-presentation [2].